ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Net Income (Common)
ScinoPharm Taiwan Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Income (Common)
NT$399.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Income (Common)
NT$1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Net Income (Common)
NT$392.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Net Income (Common)
NT$484.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Income (Common)
NT$4.3B
|
CAGR 3-Years
43%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Income (Common)
NT$847.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Net Income (Common)?
Net Income (Common)
399.4m
TWD
Based on the financial report for Sep 30, 2024, ScinoPharm Taiwan Ltd's Net Income (Common) amounts to 399.4m TWD.
What is ScinoPharm Taiwan Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-6%
Over the last year, the Net Income (Common) growth was 73%. The average annual Net Income (Common) growth rates for ScinoPharm Taiwan Ltd have been 26% over the past three years , 9% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet